Dilated cardiomyopathy update: Infectious-immune theory revisited

Heart Failure Reviews

Volumn 18, Issue 6, 2013, Pages 703-714

  Kawai, Chuichi ^a,b   Matsumori, Akira ^c,d  

^a KYOTO UNIVERSITY   (Japan)

^b TAKEDA GENERAL HOSPITAL   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d Asian Pacific Society of Cardiology   (Japan)

Author keywords

Dilated cardiomyopathy; Immune adsorption therapy; Infectious immune theory; Myocarditis; NF B decoy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN DECOY; IMMUNOGLOBULIN G3; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 2; METOPROLOL; PREDNISOLONE; PREDNISONE; SPIRONOLACTONE; TACROLIMUS; TROPONIN I; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; HEART FAILURE; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOADSORPTION; INFLAMMATION; MYOCARDITIS; NONHUMAN; PATHOGENESIS; SYSTOLIC DYSFUNCTION; VIRUS INFECTION; VIRUS MYOCARDITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; CARDIOMYOPATHY, DILATED; FEMALE; HEPATITIS C; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MYOCARDITIS; OLIGODEOXYRIBONUCLEOTIDES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84888206345     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-013-9401-z     Document Type: Article

References (70)

1. Kawai C (1971) Idiopathic cardiomyopathy. A study of the infectious-immune theory as a cause of the disease. Jpn Circ J 35:765-770. ISSN:00471828
2. Kawai C (1999) From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death. Learning from the past for the future. Circulation 99:1091-1100. doi: 10.1161/01.CIR.99.8.1091
3. Cohen J (1999) The scientific challenge of hepatitis C. Science 285:26-30. doi: 10.1126/science.285.5424.26
4. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS (1999) The prevalence of hepatitis C virus infection in the United States, 1998 through 1994. N Eng J Med 341:556-562. doi: 10.1056/NEJM199908193410802
5. Crabb C (2001) Infectious diseases. Hard-won advances spark excitement about hepatitis C. Science 294:506-507. doi: 10.1126/science.294.5542.506
6. Matsumori A, Matoba Y, Sasayama S (1995) Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92:2519-2525. doi: 10.1161/01.CIR.92.9.2519
7. Matsumori A (2005) Hepatitis C virus infection and cardiomyopathies. Circ Res 96:144-147. doi: 10.1161/01.RES.0000156077.54903.67
8. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW (2006) Myocarditis and heart failure associated with hepatitis C virus infection. J Cardiac Fail 12:293-298
9. Wang L, Geng J, Li J, Li T, Matsumori A, Chang Y, Lu F, Zhuang H (2011) The biomarker N-terminal pro-brain natriuretic peptide and liver diseases. Clin Invest Med 34(1):E30-E37
10. Matsumori A (2009) Global alert and response network for hepatitis C virus-derived heart diseases: a call to action. CVD Prev Control 4:109-118. doi: 10.1016/j.cvdpc.2009.02.002
11. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan G, George J (2003) Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125:1695-1704. doi: 10.1053/j.gastro.2003.08.032
12. Saleh A, Matsumori A, Negm H, Fouad H, Onsy A, Shalaby M (2011) Assessment of cardiac involvement of hepatitis C virus; tissue Doppler imaging and NTproBNP study. J Saudi Heart Assoc 23(4):217-223. doi: 10.1016/j.jsha.2011. 04.005
13. Matumori A, Shimada M, Obata T (2010) Leukocytes are the major target of hepatitis C virus infection: possible mechanism of multiorgan involvement including the heart. CVD Prev Control 5:51-58. doi: 10.1016/jcvdpc.2010.04.005
14. Freeman GJ, Freeman AS, Segil JM, Lee G, Whitman JF, Nadler LM (1989) B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 143:2714-2722
15. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanler LL, Somoza C (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76-79. doi: 10.1038/366076a0
16. Kishimoto C, Kuribayashi K, Masuda T, Tomioka N, Kawai C (1985) Immunologic behavior of lymphocytes in experimental viral myocarditis: significance of T lymphocytes in the severity of myocarditis and silent myocarditis in BALB/c-nu/nu mice. Circulation 71:1247-1254. doi: 10.1161/01.CIR.71.6.1247
17. Matsumori A, Kawai C (1982) An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation 66:355-360. doi: 10.1161/01.CIR.66.2.355
18. Hara M, Matsumori A, Ono K, Kido H, Hwang MW, Miyamoto T, Iwasaki A, Okada M, Nakatani K, Sasayama S (1999) Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 100:1443-1449. doi: 10.1161/01.CIR.100.13.1443
19. Kitaura-Inenaga K, Hara M, Higuchi H, Yamamoto K, Yamaki A, Ono K, Nakano A, Kinoshita M, Sasayama S, Matsumori A (2003) Gene expression of cardiac mast cell chymase and tryptase in a murine model of heart failure caused by viral myocarditis. Circ J 67:881-884. doi: 10.1253/circj.67.881
20. Matsumori A, Okada I, Kawai C, Crumpacker CS, Abelmann WF (1988) Animal models for therapeutic trials of viral myocarditis: effect of ribavirin and alpha interferon on coxsackievirus B3 and encephalomyocarditis virus myocarditis. In: Schultheiss H-P (ed) New concepts in viral heart disease. Springer, Berlin, pp 377-384
21. Newburger JW, Sanders SP, Burns JC, Parness IA, Colan SD (1989) Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin. Circulation 79:1237-1246. doi: 10.1161/01.CIR.79.6. 1237
22. Drucker N, Colan S, Lewis A, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newberger JW (1994) Gamma globulin treatment of acute myocarditis in the pediatric population. Circulation 89:252-257. doi: 10.1161/01.CIR.89.1.252
23. McNamara DM, Holublcov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosco K, Tokarczyk T, Kessler P, Mann DL, Feldman AM, for the intervention in Myocarditis and Acute Cardiomyopathy (IMAC) Investigators (2001) Controlled trial of intravenous immune globulin. Circulation 103:2254-2259. doi: 10.1161/01.CIR.103.18.2254
24. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE, The Myocarditis Treatment Trial Investigators (1995) A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 333:269-275
25. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A (2003) Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107:857-863. doi: 10.1161/01.CIR.0000048147.15962.31
26. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, Kingel K, Kandolf R, Sechtem U, Cooper LT, Boehm M (2012) Update on myocarditis. J Am Coll Cardiol 59:779-792. doi: 10.1016/j-jacc.2011.09.074
27. Cooper LT Jr, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, Menon S, Mulien GM, Jasky B, Bailey KR, Cunningham MW, Giant Cell DecGW Myocarditis Treatment Trial Investigators (2008) Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 102:1535-1539. doi: 10.1016/j.amjcard.2008.07.041
28. Cooper LT Jr, EIAmm C (2012) Giant cell myocarditis. Herz 37:632-636. doi: 10.1007/s00059-012-3658-1
29. Frustaci A, Russo A, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30:1995-2002. doi: 10.1093/eurheartj/ehp249
30. Seizer P, Klingel K, Sauter M, Westermann D, Ochmann C, Schonberger T, Schleicher R, Stellos K, Schmidt EM, Borst O, Bigalke B, Kandolf R, Langer H, Gawaz M, May AE (2012) Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus-induced myocarditis. J Mol Cell Cardilol 53:6-14. doi: 10.1016/j.yjmcc.2012.03.004. Epub 2012 Mar 15
31. Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN (2004) Protective role for interferonβ in coxsackievirus B3 infection. Circulation 110:3540-3543. doi: 10.1161/01.CIR.0000136824.73458.20
32. Liu PP, Le J, Nian M (2001) Nuclear factor-κB decoy. Infiltrating the heart of the matter in inflammatory heart disease. Circ Res 89:850-852. doi: 10.1161/hh2201.100347
33. Morishita R, Higaki J, Tomita N, Ogihara T (1998) Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 82:1023-1028. doi: 10.1161/01.RES.8210.1023
34. Morishita R (1998) Lessons from human arteries: how to design a gene therapy strategy for human treatment of cardiovascular disease. Circ Res 82:1349-1351. doi: 10.1161/01.RES.82.12.1349
35. Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, Ogihara T (2001) Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-κB binding site as a novel molecular strategy. Gene Ther 8:1635-1642
36. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T (1997) In vivo transfection of cis-element 'decoy' against nuclear factor-κB binding site prevents myocardial infarction. Nat Med 3:894-899. doi: 10.1038/nmo897-894
37. Suzuki J, Ito H, Gotoh R, Morishita R, Egashira K, Isobe M (2004) Initial clinical cases of a NF-κB decoy at the site of coronary stenting for the prevention of restenosis. Circ J 68:270-271
38. Egashira K, Suzuki J, Ito H, Aoki M, Isobe M, Morishita R (2008) Long-term follow up of initial clinical cases with NF-κB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J Gene Med 10:805-809. doi: 10.1002/jgm.1192
39. Suzuki J, Tezuka D, Morishita R, Isobe M (2009) An initial case of suppressed restenosis with nuclear factor-κB decoy transfection after percutaneous coronary intervention. J Gene Med 11:89-91. doi: 10.1002/jgm.1266
40. Suzuki J, Morishita R, Amano J, Kaneda Y, Isobe M (2000) Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 7:1847-1852
41. Suzuki J, Isobe M, Morishita R, Nagai R (2012) Application of nucleic acid drugs for organ transplantation. Curr Top Med Chem 12:1608-1612
42. Yokoseki O, Suzuki J, Kitabayashi H, Watanabe N, Wada Y, Aoki M, Morishita R, Kaneda Y, Ogihara T, Futamatsu H, Kobayashi Y, Isobe M (2001) cis element decoy against nuclear factor-κB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 89:899-906. doi: 10.1161/hh2201.099373
43. Kodama M, Matsumoto Y, Fujiwara M (1992) In vivo lymphocyte-mediated myocardial injuries demonstrated by adoptive transfer of experimental autoimmune myocarditis. Circulation 85:1918-1926. doi: 10.1161/01.CIR.85.5.1918
44. Luescher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R (2007) Drug-eluting stent and coronary thrombosis. Biological mechanisms and clinical implications. Circulation 115:1051-1058. doi: 10.1161/CIRCULATIONAHA.106.675934
45. Pasceri V, Patti G, Speciale G, Pristipino C, Richichi G, DiSciascio G (2007) Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 153:749-754
46. Leon MB (2007) Late thrombosis a concern with drug-eluting stents. J Interv Cardiol 20:26-29. doi: 10.1111/j.1540-8183.2007.00225.x
47. Mueller J, Wallukat G, Weng Y-G, Dandel M, Spiegelsberger S, Semrau S, Brandes K, Theodoridis V, Loebe M, Meyer R, Hetzer R (1997) Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 96:542-549. doi: 10.1161/01.CIR.96.2.542
48. Wallukat G, Reinke P, Doerffel WV, Luther HP, Bestvater K, Felix SB, Baumann G (1996) Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 54:191-195
49. Wallukat G, Mueller J, Hetzer R (2002) Specific removal of β1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy (letter). N Engl J Med 347:1806
50. Doerffel MV, Felix SB, Wallukat G, Brehme S, Bestvater K, Hofmann T, Kleber FX, Baumann G, Reinke P (1997) Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 95:1994-1997. doi: 10.1161/01.CIR.95.8.1994
51. Doerffel WV, Wallukat G, Doerffel Y, Felix SB, Baumann G (2004) Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up. Int J Cardiol 97:529-534. doi: 10.1061/j.ijcard.2004.03.001
52. Mueller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R (2000) Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101:385-391. doi: 10.1161/01.CIR.101.4.385
53. Staudt A, Schaeper F, Stangl V, Plegemann A, Boehm M, Merkel K, Wallukat G, Wernecke KD, Stangl K, Baumann G, Felix SB (2001) Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 103:2681-2686. doi: 10.1161/01.CIR.103.22.2681
54. Felix SB, Staudt A, Doerffel WV, Stangl V, Merkel K, Pohl M, Doecke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G (2000) Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy. Three-month results from a randomized study. J Am Coll Cardiol 35:1590-1598. doi: 10.1016/S0735-1097(00)00568-4
55. Schmaldienst S, Muellner M, Goldammer S, Spitzauer S, Banyai S, Hoerl WH, Derfler K (2001) Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology 40:513-521. doi: 10.1093/rheumatology/40.5.513
56. Staudt A, Boehm M, Knebel F, Grosse Y, Bischoff C, Hummel A, Dahm JB, Borges A, Jochmann N, Wernecke KD, Wallkat G, Baumann G, Felix SB (2002) Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyo-pathy. Circulation 106:2448-2453. doi: 10.1161/01.CIR.0000036746.49449.64
57. McCord JM (1985) Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312:159-163. doi: 10.1056/NEJM198501173120305
58. Schimke I, Mueller J, Priem F, Kruse I, Schoen B, Stein J, Kunze R, Wallukat G, Hetzer R (2001) Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 38:178-183. doi: 10.1016/S0735-1097(01)01309-2
59. Kasai H, Kashima Y, Izawa A, Tomita T, Miyashita Y, Koyama J, Takahashi M, Yoshio T, Yazaki Y, Higuchi M, Ikeda U (2012) Immunoadsorption therapy reduces oxidative stress in patients with dilated cardiomyopathy. World J Cardiovasc Dis 2:305-312. doi: 10.4236/wjcd.2012.24048
60. Nagatomo Y, Baba A, Ito H, Naito K, Yoshizawa A, Kurita Y, Nakamura I, Monkawa T, Matsubara T, Wakabayashi Y, Ogawa S, Akaishi M, Yoshikawa T (2011) Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy. J Clin Apher 26:1-8. doi: 10.1002/jca.20268
61. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama A, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice. Science 291:319-322. doi: 10.1126/science.291.5502.319
62. Okazaki T, Tanaka Y, Nisio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477-1483. doi: 10.1038/nm955
63. Matsumori A, Shimada T, Hattori H, Shimada M, Mason JW (2011) Autoantibodies against cardiac troponin I in patients presenting with myocarditis. CVD Prev Control 6:41-46. doi: 10.1016/j.cvdpc.2011.02.004
64. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation 112:1825-1852. doi: 10.1161/CIRCULATIONAHA.105. 167587
65. Bonow RO, Ganiats TG, Beam CT, Blake K, Casey DE Jr, Goodlin SJ, Grady KL, Hundley RF, Jessup M, Lynn TE, Masoudi FA, Nilasena D, Pina IL, Rockswold PD, Sadwin LB, Sikkema JD, Sincak CA, Spertus J, Torcson PJ, Torres E, Williams MK, Wong JB (2012) ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. Circulation 125:2382-2401. doi: 10.1161/CIR.0b013e3182507bec
66. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL (2000) β-Adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 101:2103-2109. doi: 10.1161/01.CIR.101.17.2103
67. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT (2002) Aldosterone-induced inflammation in the rat heart. Am J Pathol 161:1773-1781
68. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717. doi: 10.1056/NEJM199909023411001
69. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Pittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321. doi: 10.1056/NEJMoa030207
70. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN (2002) Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106:2967-2972. doi: 10.1161/01.CIR.0000039104.56479.42